Archer-Daniels-Midland Co (ADM) earnings date, results and what the price requires
NYSE · SEC CIK 0000007084 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $6.39B | $908.0M | $1.87 | Filing |
| Mar 31, 2026 | May 5, 2026 | $6.14B | $298.0M | $0.62 | Filing |
| Dec 31, 2025 | Feb 3, 2026 | $6.05B | $456.0M | $0.95 | Filing |
| Sep 30, 2025 | Nov 4, 2025 | $6.42B | $108.0M | $0.22 | Filing |
| Jun 30, 2025 | Aug 5, 2025 | $6.34B | $219.0M | $0.45 | Filing |
| Mar 31, 2025 | May 6, 2025 | $6.15B | $295.0M | $0.61 | Filing |
| Dec 31, 2024 | Feb 4, 2025 | $6.28B | $567.0M | $1.21 | Filing |
| Sep 30, 2024 | Nov 5, 2024 | $5.99B | $18.0M | $0.04 | Filing |
What would Archer-Daniels-Midland Co have to report for its valuation to change?
At $82.93, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 14.1% a year, to $7.09. On that path the next quarter needs diluted EPS near $0.25, against $0.22 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 14.1% | 14.1% |
| EPS needed in final year | $7.09 | $7.09 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ADM goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.